For the 5-FU plus thymidine regimen ,  patients were evaluated every 4 weeks ,  while for all other regimens ,  this evaluation occurred every 5 weeks .
Each combination regimen was compared to treatment with 5- FU alone with respect to duration of survival following randomization ,  time to disease progression. objective regression rates among measurable patients ,  and toxic reactions .
